High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform offers user-friendly software that supports healthcare staff in their daily operations while facilitating the integration of innovative technologies such as artificial intelligence, big data, telemedicine, patient applications, and wearables. By streamlining workflows and automating various tasks, Avelios Medical aims to significantly improve both patient outcomes and healthcare research, making it a valuable resource for hospitals and clinics seeking to modernize their services.
Laclarée
Seed Round in 2025
Laclarée Vision specializes in the development of adaptive eyeglasses designed to correct presbyopia. Founded in 2016 and based in Lyon, France, the company utilizes patented fluid technology to create lenses that automatically adjust in real-time to various viewing distances. This innovative approach addresses the needs of individuals aged 45 and older who often find traditional solutions, such as progressive lenses or multiple pairs of glasses, unsatisfactory. By combining adaptive lens technology with refractive correction for conditions like astigmatism, myopia, and hyperopia, Laclarée aims to provide a clearer vision experience for its users.
Lindis Blood Care
Venture Round in 2024
Lindis Blood Care is focused on enhancing the outcomes of cancer surgeries through the development of a medical device that removes cancer cells from salvaged blood. This innovation facilitates the possibility of autologous blood transfusions, allowing cancer patients to receive their own blood collected during surgery. By enabling self-blood administration, Lindis Blood Care aims to improve the safety and effectiveness of blood transfusions for patients undergoing tumor removal, ultimately supporting better recovery and health outcomes.
Sedivention
Pre Seed Round in 2024
Sedivention is a medical technology company specializing in the development of minimally invasive devices for obesity treatment. Their flagship product is a cryo catheter that, in a single, brief procedure akin to a gastroscopy, freezes and ablates the gastric branches of the vagus nerve, reducing hunger and promoting weight loss. This outpatient procedure offers a less invasive alternative to traditional obesity treatments.
Lymphatica Medtech
Series B in 2024
Lymphatica Medtech SA is a Swiss company focused on designing and manufacturing medical devices for the treatment of lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed LymphoDrain, an innovative medical device that aims to re-establish lymphatic circulation. This system includes an active implantable lymphatic bypass, featuring a magnetically controlled micropump and subcutaneous catheters that facilitate the internal drainage of lymphatic fluid from multiple points within the affected limb. Lymphatica Medtech also produces essential components for LymphoDrain, such as the micropump head and wearable controller, providing a minimally invasive solution for individuals suffering from persistent lymphedema.
CustomSurg
Seed Round in 2024
CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.
Altavo
Series A in 2024
Altavo is a medical device startup focused on creating artificial voice solutions for individuals who have lost their ability to speak due to surgery or disease. By leveraging advanced machine learning and cutting-edge sensor technology, Altavo develops custom, natural-sounding voices that enable voiceless individuals to communicate effectively. The company's innovative approach combines speech recognition and synthesis, significantly enhancing the quality of life for those with speech disorders.
RAYDIAX
Seed Round in 2023
RAYDIAX specializes in the development of advanced therapy-assist CT systems aimed at enhancing the safety and effectiveness of minimally invasive medical interventions. The company’s imaging solutions integrate both 2D and 3D X-ray live imaging with a sophisticated navigation system, allowing healthcare providers to perform precise and efficient tumor interventions. By focusing on reducing the risk of postoperative complications, RAYDIAX's technology contributes to shorter hospital stays and faster recovery times for patients. The company's commitment to improving the quality of care supports clinicians in delivering better outcomes in cancer therapy.
Kranus Health
Series A in 2023
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
C-mo Medical Solutions
Seed Round in 2022
C-mo Medical Solutions specializes in developing monitoring devices aimed at providing a comprehensive assessment of cough patterns in patients. The company's portable and ergonomic wearables facilitate long monitoring periods and the detection of distinctive cough patterns. With fully automated analysis capabilities, these devices enable healthcare professionals to deliver accurate diagnoses and prescribe personalized treatment plans. By addressing key use-cases throughout the patient management lifecycle, C-mo Medical Solutions plays a significant role in enhancing cough-related healthcare.
Kranus Health
Series A in 2022
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
Lindis Blood Care
Venture Round in 2022
Lindis Blood Care is focused on enhancing the outcomes of cancer surgeries through the development of a medical device that removes cancer cells from salvaged blood. This innovation facilitates the possibility of autologous blood transfusions, allowing cancer patients to receive their own blood collected during surgery. By enabling self-blood administration, Lindis Blood Care aims to improve the safety and effectiveness of blood transfusions for patients undergoing tumor removal, ultimately supporting better recovery and health outcomes.
Altavo
Seed Round in 2022
Altavo is a medical device startup focused on creating artificial voice solutions for individuals who have lost their ability to speak due to surgery or disease. By leveraging advanced machine learning and cutting-edge sensor technology, Altavo develops custom, natural-sounding voices that enable voiceless individuals to communicate effectively. The company's innovative approach combines speech recognition and synthesis, significantly enhancing the quality of life for those with speech disorders.
Avelios Medical
Seed Round in 2021
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform offers user-friendly software that supports healthcare staff in their daily operations while facilitating the integration of innovative technologies such as artificial intelligence, big data, telemedicine, patient applications, and wearables. By streamlining workflows and automating various tasks, Avelios Medical aims to significantly improve both patient outcomes and healthcare research, making it a valuable resource for hospitals and clinics seeking to modernize their services.
Reactive Robotics
Venture Round in 2021
Reactive Robotics GmbH, founded in April 2015 and based in Gilching, Germany, specializes in the design, manufacture, and sale of rehabilitation robots aimed at early movement rehabilitation following neurological injuries and orthopedic surgeries. The company focuses on gait rehabilitation for neurological patients and assists orthopedic patients recovering from joint replacements. With a team that has over 12 years of experience in rehabilitation robotics, Reactive Robotics benefits from a robust clinical network and a group of advisors who provide guidance on engineering, legal matters, and medical device registration. Additionally, the company develops AI-driven robotic systems that support very early mobilization therapy, facilitating faster recovery for patients in intensive care units while alleviating the workload of nursing staff.
Kranus Health
Seed Round in 2021
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
Lymphatica Medtech
Series A in 2020
Lymphatica Medtech SA is a Swiss company focused on designing and manufacturing medical devices for the treatment of lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed LymphoDrain, an innovative medical device that aims to re-establish lymphatic circulation. This system includes an active implantable lymphatic bypass, featuring a magnetically controlled micropump and subcutaneous catheters that facilitate the internal drainage of lymphatic fluid from multiple points within the affected limb. Lymphatica Medtech also produces essential components for LymphoDrain, such as the micropump head and wearable controller, providing a minimally invasive solution for individuals suffering from persistent lymphedema.
WISE
Series C in 2020
WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.
Kumovis
Series A in 2020
Kumovis is a medical technology company focused on advancing the field of 3D printing for industrial and medical applications. It has developed a specialized 3D printing system that integrates clean room technology, allowing for the precise processing of high-performance polymers. This innovation enables the creation of patient-customized implants, facilitating more convenient and effective medical operations in hospitals. Through its cutting-edge technology, Kumovis aims to enhance the capabilities of medical professionals and improve patient outcomes.
iATROS
Seed Round in 2020
iATROS GmbH is a Munich-based company founded in 2019 that specializes in developing a mobile application and platform designed to connect cardiology patients with medical caregivers. The application offers a range of services including therapy and medication planning, progress tracking, ECG diagnosis, and maintenance of health data such as blood pressure and glucose levels. It also facilitates consultations with physicians, ensuring patients have 24/7 access to healthcare professionals. As the prevalence of cardiovascular diseases increases, iATROS aims to improve the lives of both chronic and acute cardiovascular patients while contributing to the reduction of healthcare costs. The company leverages smart health trackers and advanced AI analytics to enhance treatment outcomes, allowing patients to manage common heart conditions effectively.
Biograil
Seed Round in 2020
Biograil, founded in 2019 and led by CEO Karsten Lindhardt, specializes in developing a medical device that innovatively replaces traditional injection systems for administering medications. Utilizing an injection molding technique, the device is encapsulated in a standard-sized capsule and employs the body's natural peristaltic forces to deliver biologics directly into the gastrointestinal wall. This approach eliminates the need for mechanical moving components, allowing for a painless and efficient method of drug delivery to patients.
Lindis Blood Care
Venture Round in 2019
Lindis Blood Care is focused on enhancing the outcomes of cancer surgeries through the development of a medical device that removes cancer cells from salvaged blood. This innovation facilitates the possibility of autologous blood transfusions, allowing cancer patients to receive their own blood collected during surgery. By enabling self-blood administration, Lindis Blood Care aims to improve the safety and effectiveness of blood transfusions for patients undergoing tumor removal, ultimately supporting better recovery and health outcomes.
Laclarée
Seed Round in 2019
Laclarée Vision specializes in the development of adaptive eyeglasses designed to correct presbyopia. Founded in 2016 and based in Lyon, France, the company utilizes patented fluid technology to create lenses that automatically adjust in real-time to various viewing distances. This innovative approach addresses the needs of individuals aged 45 and older who often find traditional solutions, such as progressive lenses or multiple pairs of glasses, unsatisfactory. By combining adaptive lens technology with refractive correction for conditions like astigmatism, myopia, and hyperopia, Laclarée aims to provide a clearer vision experience for its users.
Zahnarzt-Helden
Seed Round in 2019
Zahnarzt-Helden GmbH, established in 2017 and located in Bielefeld, Germany, operates an independent online platform that assists dentists in securing optimal investments for their practices. The platform offers a wide range of products, including Orthopantomograms (OPG), deep vein thrombosis (DVT) equipment, Cephalometric X-rays, intraoral X-rays, intraoral scanners, autoclaves, thermodisinfectors, CAD/CAM systems, and various technical services. Zahnarzt-Helden provides expert consultation to help dentists select appropriate products, negotiate with manufacturers and dealers, and organize installation and maintenance services. Additionally, the company ensures reliable technical support, promoting transparency and helping clients avoid hidden costs, akin to other comparison platforms.
8sense
Seed Round in 2019
8sense is a developer of a physical coaching device that focuses on improving back health through a combination of position and movement analysis. The company offers a smart back sensor that provides real-time interaction and training, motivating users to prioritize their posture before issues arise. Utilizing a wearable device and a coaching platform, 8sense analyzes movements and posture, delivering personalized recommendations based on scientific principles. This innovative approach encourages users to adopt an active and dynamic sitting posture, thereby promoting better overall back health in office environments.
Kumovis
Seed Round in 2018
Kumovis is a medical technology company focused on advancing the field of 3D printing for industrial and medical applications. It has developed a specialized 3D printing system that integrates clean room technology, allowing for the precise processing of high-performance polymers. This innovation enables the creation of patient-customized implants, facilitating more convenient and effective medical operations in hospitals. Through its cutting-edge technology, Kumovis aims to enhance the capabilities of medical professionals and improve patient outcomes.
Implandata Ophthalmic Products
Series C in 2018
Implandata Ophthalmic Products GmbH is a medical device company based in Hanover, Germany, founded in 2010. It specializes in developing innovative solutions for the treatment and management of glaucoma, a prevalent eye disease. The company's flagship product, Eyemate, is an implantable micro sensor designed for continuous intraocular pressure measurement. This biocompatible device allows for 24-hour monitoring without compromising the patient's vision or overall well-being. By integrating advanced medical technology with information technology, Implandata aims to enhance the efficiency of glaucoma therapy, benefiting patients, their families, and caregivers. The company's focus on addressing unmet needs in glaucoma care positions it as a significant player in the ophthalmic medical device sector.
Reactive Robotics
Series B in 2017
Reactive Robotics GmbH, founded in April 2015 and based in Gilching, Germany, specializes in the design, manufacture, and sale of rehabilitation robots aimed at early movement rehabilitation following neurological injuries and orthopedic surgeries. The company focuses on gait rehabilitation for neurological patients and assists orthopedic patients recovering from joint replacements. With a team that has over 12 years of experience in rehabilitation robotics, Reactive Robotics benefits from a robust clinical network and a group of advisors who provide guidance on engineering, legal matters, and medical device registration. Additionally, the company develops AI-driven robotic systems that support very early mobilization therapy, facilitating faster recovery for patients in intensive care units while alleviating the workload of nursing staff.
KSK Diagnostics
Series A in 2017
KSK Diagnostics GmbH, established in 2014 and based in Hamburg, Germany, specializes in the development of molecular point-of-care diagnostic assays aimed at diagnosing infectious diseases and cancer. The company utilizes isothermal amplification technology to create rapid tests that enable healthcare professionals to make timely diagnoses, often within 30 minutes, thereby facilitating prompt treatment decisions. In addition to its diagnostic assays, KSK Diagnostics offers customizable services, including the development of nucleic acid-based tests using real-time PCR or RT-PCR, as well as verification and validation studies and product enhancement services for other organizations in the healthcare sector. As a pioneer in this field, KSK Diagnostics is dedicated to improving patient-oriented diagnostics through innovative technologies.
CryoTherapeutics
Series B in 2016
CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.
Reactive Robotics
Series A in 2016
Reactive Robotics GmbH, founded in April 2015 and based in Gilching, Germany, specializes in the design, manufacture, and sale of rehabilitation robots aimed at early movement rehabilitation following neurological injuries and orthopedic surgeries. The company focuses on gait rehabilitation for neurological patients and assists orthopedic patients recovering from joint replacements. With a team that has over 12 years of experience in rehabilitation robotics, Reactive Robotics benefits from a robust clinical network and a group of advisors who provide guidance on engineering, legal matters, and medical device registration. Additionally, the company develops AI-driven robotic systems that support very early mobilization therapy, facilitating faster recovery for patients in intensive care units while alleviating the workload of nursing staff.
Cevotec
Seed Round in 2016
Cevotec GmbH, founded in 2015 and based in Munich, Germany, specializes in the design and automation of carbon fiber composites and reinforcements for various industries, including aerospace, medical devices, and sports. The company utilizes its Fiber Patch Placement technology to provide manufacturers with advanced solutions for high-volume production of complex composites. Cevotec's SAMBA systems enable fully automated fiber layup, which significantly enhances production efficiency and quality by allowing the creation of intricate 3D geometries and multi-material laminates. Their technology-specific CAD-CAM software, ARTIST STUDIO, facilitates the generation of patch-based fiber laminates and automates robot programming. By transitioning from manual layup to Cevotec's systems, clients can achieve substantial cost and time savings ranging from 20% to 60%. Additionally, Cevotec offers a comprehensive service portfolio that includes customizations tailored to specific applications and development support based on finite element analysis.
CorTec
Series B in 2016
CorTec is a developer and manufacturer focused on creating advanced medical devices for neuromodulation and brain-computer interfaces. The company has spent a decade on research and development, culminating in the innovative CorTec Brain Interchange™ System. This unique platform allows researchers and clinicians to devise novel therapies for neurological disorders. Central to this system are the °AirRay™ electrode arrays, which are laser-structured, soft, and flexible, ensuring a gentle fit to the brain's contours for reliable, permanent recordings. The implanted electronics, protected by biocompatible ceramic encapsulation, preprocess data and include a custom microchip developed with the University of Ulm. This microchip amplifies and digitizes neuronal signals across multiple channels, while eliminating the need for battery replacements through an external inductive power supply. Furthermore, CorTec provides additional support, services, and components related to the Brain Interchange System to Medtech companies and startups in the neurotechnology sector.
Multiphoton Optics
Series A in 2015
Multiphoton Optics GmbH specializes in the development and sale of 3D printing equipment and software for additive manufacturing. The company's technology enables the creation of complex three-dimensional structures across various materials, including polymers, hybrid materials, glasses, and metals. Key products include the LithoProf3D printing platform, along with the LithoStream3D and LithoSoft3D software solutions, which cater to applications in photonics, biomedicine, life sciences, and functional materials. Additionally, Multiphoton Optics provides services such as prototyping, engineering support, and consulting to enhance customer experience. Founded in 2013 in Wurzburg, Germany, the company has established a reputation for high-precision opto-electronics assembly and innovative optical component packaging solutions.
Bomedus
Series B in 2015
Bomedus is a Germany-based medical device company established in 2011, focused on improving mobility for individuals suffering from chronic pain, particularly back pain. The company's innovative devices employ an electro-therapeutic method aimed at providing permanent and sustainable pain reduction. By non-invasively modulating pathologically altered neuronal impulses, Bomedus seeks to enhance the quality of life for patients experiencing chronic discomfort.
Eyetronic Therapie
Venture Round in 2015
EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.
Sonormed GmbH
Series A in 2015
Sonormed GmbH is a medical technology company based in Hamburg, Germany, that specializes in digital audiology. Founded in 2012, the company has developed Tinnitracks, a web application designed to assist users in filtering music for tinnitus therapy, which is supported by neuroscientific research. This innovative solution not only helps users select appropriate music tracks for therapeutic purposes but also automatically evaluates the music files to assess their therapeutic potential, providing guidance on the suitability of each track for tinnitus treatment.
Immunservice
Series C in 2015
Immunservice GmbH is engaged in the development and commercialization of biomimetic treatments aimed at cancer and infectious diseases. The company specializes in creating therapies based on immune hormones, particularly focusing on interleukin-2. Its flagship product, Pulmoleukin, is designed to prevent suffocation in patients with lung tumors by leveraging natural biomimetic approaches. Immunservice also addresses various orphan disease indications and offers services related to patent applications, biomimetic therapies, and clinical development. Founded in 2004 and based in Hamburg, Germany, the company emphasizes research on immune hormone interleukin-2 and provides insights for the advancement of diagnostic and pharmaceutical applications.
oncgnostics
Series A in 2015
Oncgnostics GmbH, founded in 2012 and based in Jena, Germany, specializes in developing molecular assays that leverage epigenetic biomarkers for early and reliable cancer diagnostics. The company focuses on in vitro diagnostic (IVD) tests that aid in screening, therapeutic decision-making, and follow-up care in cancer treatment. Notably, Oncgnostics has developed GynTect, a diagnostic tool that facilitates the swift and accurate detection of cervical cancer and its precancerous stages. The tests are based on identifying specific DNA regions that are methylated in cancerous and precancerous cells, utilizing established PCR-based technologies suitable for routine molecular diagnostic laboratories. Through its innovative approach, Oncgnostics aims to enhance cancer diagnosis and improve patient outcomes.
Implandata Ophthalmic Products
Series B in 2014
Implandata Ophthalmic Products GmbH is a medical device company based in Hanover, Germany, founded in 2010. It specializes in developing innovative solutions for the treatment and management of glaucoma, a prevalent eye disease. The company's flagship product, Eyemate, is an implantable micro sensor designed for continuous intraocular pressure measurement. This biocompatible device allows for 24-hour monitoring without compromising the patient's vision or overall well-being. By integrating advanced medical technology with information technology, Implandata aims to enhance the efficiency of glaucoma therapy, benefiting patients, their families, and caregivers. The company's focus on addressing unmet needs in glaucoma care positions it as a significant player in the ophthalmic medical device sector.
Preventicus
Seed Round in 2014
Preventicus GmbH, founded in 2014 and headquartered in Jena, Germany, develops innovative health solutions that utilize smartphone and smartwatch technologies to monitor vital parameters. The company's main product, Preventicus Heartbeats, is a class I medical device designed to identify atrial fibrillation, a condition that increases the risk of stroke. This smart screening solution allows users to check their heart rhythm quickly and conveniently, requiring no additional accessories. The software applications are certified medical devices and have demonstrated a level of accuracy previously achievable only by physicians, making them valuable for private users, corporate clients in occupational health management, and OEM customers. Preventicus focuses on early preclinical risk screening for lifestyle-related illnesses, including heart attacks and strokes, effectively enhancing personal health management.
Medineering
Seed Round in 2014
Medineering is a medical technology company based in Munich, Germany, specializing in innovative robotic systems for minimally invasive head surgery. Founded in 2014, the company develops, patents, and sells a modular range of surgical manipulators that enable clinics and surgeons to customize the level of automation and functionality based on their specific surgical needs and budget constraints. Its product portfolio includes an intelligent positioning arm and compact, application-specific robots designed to assist surgeons in navigating complex anatomical regions. Medineering aims to enhance the potential of minimally invasive surgery through advanced robotic solutions that optimize surgical access and improve working conditions in the operating room.
Coramaze Technologies
Seed Round in 2014
Coramaze Technologies is a medical device company focused on developing innovative solutions for heart diseases. Founded in 2013 and headquartered in Munich, Germany, the company is working on a minimally invasive valve repair system aimed at treating patients with structural heart valve diseases. Their flagship product, the Mitramaze valve repair system, is a catheter-based device designed for implantation directly into the beating heart, catering to inoperable and asymptomatic patients. Additionally, Coramaze is advancing an adaptive tricuspid valve repair device known as Tripair, which is designed to be anchored in the right atrium, facilitating a quick and straightforward procedure accessible in catheterization labs. This technology aims to address functional mitral regurgitation resulting from heart enlargement due to conditions like heart attacks or heart failure, thus providing less invasive treatment options for patients who might otherwise go without proper care.
Scopis
Series A in 2013
Scopis GmbH, founded in 2010 as a joint spin-off of Charité University Clinic Berlin and Fraunhofer IPK, specializes in developing and manufacturing navigation systems for minimally invasive surgeries, particularly in the fields of ENT, spine, cranio-maxillofacial, and neurosurgery. The company offers a range of products, including the Scopis TGS for navigated functional endoscopic sinus surgery and the Hybrid Navigation System, which integrates with endoscopic towers to provide high-definition documentation. Scopis also produces various EM instruments, such as precision pointers, malleable suction tubes, and tracking devices. Additionally, the company provides planning software that facilitates the surgical process by allowing users to create and execute plans in the operating theater. Scopis operates a worldwide distribution network and is based in Berlin, Germany, as a subsidiary of Stryker Corporation.
Synoste
Venture Round in 2013
Synoste Oy, founded in 2007 and based in Espoo, Finland, specializes in developing innovative solutions for the treatment of skeletal deformities. The company focuses on patient-friendly technologies for various conditions, including congenital limb discrepancies, trauma-related injuries, and craniomaxillofacial deformities. Its flagship product is a third-generation limb-lengthening system that incorporates smart materials, designed to enhance patient comfort during the often-complicated lengthening procedure. This advanced device aims to reduce complications and facilitate quicker recovery, making it a significant improvement over traditional methods. As a subsidiary of Globus Medical, Inc., Synoste continues to advance its mission of providing effective and less painful treatment options for individuals with skeletal deformities.
dentaZOOM
Seed Round in 2013
dentaZOOM specializes in the development and distribution of compact surgical microscopes tailored for dental surgery. The company's products are designed to be small, lightweight, and monocular, featuring an integrated LED light system. This innovative design allows dental professionals to incorporate the microscopes seamlessly into their treatment processes, enhancing visibility and precision during procedures. By prioritizing convenience and functionality, dentaZOOM aims to improve the overall efficiency of dental care.
Photonics Healthcare
Venture Round in 2013
Photonics Healthcare GmbH is a medical device company based in Garching, Germany, specializing in the development and commercialization of clinical monitors for measuring cellular oxygen levels. Its primary product, the COMET Monitor, enables healthcare professionals to non-invasively assess cellular oxygen metabolism, including both availability and consumption, at the bedside. This technology is crucial for detecting hypoxia in tissue cells, allowing doctors to evaluate tissue vitality and make informed decisions regarding treatment interventions. By providing real-time data on cellular oxygen dynamics, Photonics Healthcare supports the timely prevention of organ failure and aims to enhance patient care. Additionally, the company offers contract research programs to further advance its medical technologies.
PERORA
Seed Round in 2013
PERORA GmbH is a biotechnology company based in Heidelberg, Germany, established in 2013. The company develops innovative solutions for weight management and obesity treatment, notably through a polymer-based fat-binding medical device. Additionally, PERORA produces and markets REDIA, a nutritional supplement recognized for its health benefits, specifically in lowering postprandial blood sugar levels. This product has received patents in the European Union, the United States, and other countries, and has been clinically validated for use in patients with type 2 diabetes. REDIA is available for purchase in Germany through its website and various online pharmacies. PERORA aims to expand its offerings by establishing a subscription model for the self-management of chronic, age-related metabolic health in Europe and seeks to license its products for international markets.
Middle Peak Medical
Series A in 2013
Middle Peak Medical is a privately held medical device company dedicated to developing innovative solutions for mitral valve disease. The company focuses on creating a proprietary device designed to address unmet needs in treating mitral valve regurgitation. This novel technology aims to restore mitral valve competence in both functional and degenerative conditions by providing a new posterior surface for the anterior leaflet to seal properly. The device is applicable in both percutaneous catheter-based interventions and minimally invasive or open-heart cardiac surgeries, positioning Middle Peak Medical as a key player in advancing treatment options for patients with mitral valve disorders.
Eyetronic Therapie
Series B in 2013
EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.
Dolosys
Venture Round in 2013
Dolosys GmbH is a medical technology company based in Berlin, Germany, that specializes in developing and manufacturing devices for the objective measurement and management of pain. The company's innovative equipment aims to enhance pain therapy for sedated intensive care patients and those suffering from chronic pain. By providing healthcare organizations with effective tools for pain monitoring and stimulation, Dolosys enables improved pain management alternatives, ultimately contributing to better patient care and outcomes.
WISE
Venture Round in 2013
WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.
CryoTherapeutics
Series A in 2013
CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.
Advanova
Series A in 2013
Advanova GmbH, founded in 2012 and based in Erlangen, Germany, specializes in developing software that facilitates access to patients' electronic medical records through mobile devices. The company's flagship product, VMobil, is designed to streamline the management of medical records by enabling electronic documentation on devices such as tablets. This technology allows medical professionals to quickly access comprehensive patient information, including treatment status, thereby reducing search time, minimizing costs, and decreasing the potential for errors in patient care.
Drug Response Dx
Series A in 2013
Drug Response Dx, headquartered in Hennigsdorf, Germany, was founded in February 2012 by a team of experts including Dr. Zoltán Konthur, Dr. Jörg-M. Hollidt, Dr. Karl Skriner, and Dr. Joachim Rautter. The company specializes in developing biomarker tests specifically designed to evaluate treatment outcomes for rheumatoid arthritis. Their tests utilize a protein that predicts the individual effectiveness of TNF-alpha inhibitors, allowing for personalized treatment planning prior to medication administration. This approach facilitates timely initiation of treatment and increases the likelihood of positive patient outcomes. The company's biomarker set is prevalidated, and they have established proof of concept using serum samples from rheumatoid arthritis patients.
InnoCyte
Series A in 2012
InnoCyte - Technologies for automated Cell Culture. They have the strong belief that automated cell culture could be of inestimable value for cell processing in labs all over the world. InnoCyte brings automated cell culture to the masses - within a benchtop designed, reliable and affordable device.
Topsfield Medical GmbH
Seed Round in 2012
Topsfield Medical GmbH, founded in 2012 and based in Berlin, Germany, is an orthopedic startup focused on developing innovative medical devices aimed at extending the life of implants. The company specifically addresses the issue of premature implant loosening by enhancing the methods of prosthesis fixation. Topsfield Medical's solutions are designed to improve the durability and effectiveness of orthopedic implants, contributing to better patient outcomes in orthopedic procedures.
KonTEM
Venture Round in 2012
KonTEM specializes in the development of phase contrast systems designed for transmission electron microscopes. These advanced systems significantly enhance image quality, making them particularly beneficial for applications in the fields of life sciences and soft materials. By improving the clarity and detail of microscopic images, KonTEM's technology supports researchers and professionals in their scientific endeavors.
oncgnostics
Seed Round in 2012
Oncgnostics GmbH, founded in 2012 and based in Jena, Germany, specializes in developing molecular assays that leverage epigenetic biomarkers for early and reliable cancer diagnostics. The company focuses on in vitro diagnostic (IVD) tests that aid in screening, therapeutic decision-making, and follow-up care in cancer treatment. Notably, Oncgnostics has developed GynTect, a diagnostic tool that facilitates the swift and accurate detection of cervical cancer and its precancerous stages. The tests are based on identifying specific DNA regions that are methylated in cancerous and precancerous cells, utilizing established PCR-based technologies suitable for routine molecular diagnostic laboratories. Through its innovative approach, Oncgnostics aims to enhance cancer diagnosis and improve patient outcomes.
Seiratherm
Venture Round in 2012
Seiratherm is a privately held medical technology company located in Herzogenaurach, Germany, specializing in fluid and body-temperature management devices. The company's innovative devices are designed to quickly and safely regulate the core body temperature of critically ill or surgical patients, targeting pre-set treatment goals. By effectively managing body temperature, Seiratherm's devices help lower metabolic rates, which can reduce neurological damage and enhance the treatment of conditions such as hypothermia, normothermia, and hyperthermia. This approach enables healthcare professionals to deliver more efficient and effective care to patients in critical situations.
Implandata Ophthalmic Products
Series A in 2012
Implandata Ophthalmic Products GmbH is a medical device company based in Hanover, Germany, founded in 2010. It specializes in developing innovative solutions for the treatment and management of glaucoma, a prevalent eye disease. The company's flagship product, Eyemate, is an implantable micro sensor designed for continuous intraocular pressure measurement. This biocompatible device allows for 24-hour monitoring without compromising the patient's vision or overall well-being. By integrating advanced medical technology with information technology, Implandata aims to enhance the efficiency of glaucoma therapy, benefiting patients, their families, and caregivers. The company's focus on addressing unmet needs in glaucoma care positions it as a significant player in the ophthalmic medical device sector.
Eyesight & Vision GmbH
Seed Round in 2011
Eyesight & Vision GmbH, founded in 2010 and based in Nürnberg, Germany, specializes in the development and marketing of advanced diagnostic equipment for refractive errors during cataract surgery. The company’s flagship product, the Intraoperative Ocular Wavefront Aberrometer (I-O-W-A), enables surgeons to optimize the selection and positioning of intraocular lenses (IOLs) with enhanced predictability of refractive outcomes and improved patient satisfaction. Utilizing patented "flying spot" technology, the system provides real-time measurements of refractive power and incorporates binocular input reflection through a 3D Head-Up Display, ensuring seamless integration with existing surgical microscopes. This innovative approach facilitates efficient and accurate measurements during surgery, ultimately contributing to better surgical results.
GME German Medical Engineering
Venture Round in 2011
GME German Medical Engineering GmbH, established in 2011 and headquartered in Erlangen, Germany, specializes in the development and marketing of advanced laser and light systems for dermatological applications. The company’s flagship product, the Linscan 808, is a versatile diode laser designed for permanent hair removal, skin tightening, and the treatment of skin conditions such as psoriasis and vitiligo. GME's systems are notable for their ease of use, featuring Plug & Play installation, intelligent software, and WiFi update capabilities. Their compact design facilitates transport, making them suitable for various clinical environments. All products are developed and manufactured in Germany, adhering to stringent medical device approval standards. GME markets its products globally through a network of partner companies, providing innovative solutions to dermatologists in both aesthetic and medical fields.
CorTec
Seed Round in 2011
CorTec is a developer and manufacturer focused on creating advanced medical devices for neuromodulation and brain-computer interfaces. The company has spent a decade on research and development, culminating in the innovative CorTec Brain Interchange™ System. This unique platform allows researchers and clinicians to devise novel therapies for neurological disorders. Central to this system are the °AirRay™ electrode arrays, which are laser-structured, soft, and flexible, ensuring a gentle fit to the brain's contours for reliable, permanent recordings. The implanted electronics, protected by biocompatible ceramic encapsulation, preprocess data and include a custom microchip developed with the University of Ulm. This microchip amplifies and digitizes neuronal signals across multiple channels, while eliminating the need for battery replacements through an external inductive power supply. Furthermore, CorTec provides additional support, services, and components related to the Brain Interchange System to Medtech companies and startups in the neurotechnology sector.
Microstim
Venture Round in 2011
Microstim GmbH specializes in developing implantable myostimulators aimed at providing tissue maintenance and functional support for the heart. The company focuses on advanced microcontroller technology for the acquisition and processing of data, as well as the control of cardiac and muscle stimulation impulses. Its innovative devices facilitate wireless communication within the body, enhancing patient monitoring and care. The myostimulators are designed to assist muscle-powered cardiac functions, allowing patients to monitor stimulation levels and preventing overstimulation that could jeopardize therapy. Microstim GmbH gained recognition for its business model by winning a national business plan contest in 2008, highlighting its potential in the medical technology sector.
Transcatheter Technologies
Series A in 2011
TRANSCATHETER TECHNOLOGIES is developing a unique aortic valve implantation system that will increase the safety and durability of aortic valve implantation. The TRINITY repositionable transcatheter aortic valve system is at the forefront of next-generation transcatheter valve implantation technology. In the near future, transcatheter valve implantation will become the preferred therapy for aortic valve implantation, and TRANSCATHETER TECHNOLOGIES‘ goal is to provide the most advanced technology available.
SAW Instruments
Series B in 2011
SAW Instruments specializes in the development, manufacture, and distribution of analytical systems designed for the life sciences sector. The company's innovative equipment enables label-free analysis of biomolecular interactions, offering a combination of high sensitivity, stability, and user-friendliness. SAW Instruments' products are utilized by leading research institutions in Germany and Switzerland, reflecting their effectiveness and reliability in advanced scientific research.
Gilupi
Series C in 2011
GILUPI GmbH is a medical device company based in Potsdam, Germany, specializing in the development and production of diagnostic products for the in vivo isolation of rare cells from circulating blood. The company's devices are specifically designed to isolate tumor cells by utilizing antibodies bound to a nano-detector, allowing for precise identification of circulating tumor cells. This technology enables healthcare professionals to perform in vivo isolation, supporting tailored therapeutic approaches for patients. GILUPI's products are CE certified, ensuring compliance with European health standards.
Heppe Medical Chitosan
Series B in 2010
Heppe Medical Chitosan GmbH, based in Halle, Germany, specializes in the development, production, and sale of biopolymers derived from chitin and chitosan for the cosmetic and pharmaceutical industries. Founded in 2005, the company produces pure chitin and chitosan, along with their derivatives and nanoparticulate forms, adhering to Good Manufacturing Practice (GMP) standards. These biodegradable and non-toxic biopolymers possess unique properties, such as bacteriostatic effects and the ability to bond with proteins and heavy metals. Heppe Medical Chitosan's products are utilized in applications including wound dressing, drug delivery, and tissue engineering, allowing for innovative solutions in healthcare and beauty.
Curefab Technologies
Venture Round in 2010
Curefab is a developer of medical technologies focused on enhancing the assessment of diagnostic image data. The company's innovative solutions aim to improve diagnostic certainty and facilitate early detection of cardiovascular and oncological diseases. By providing tools for stroke prevention and early diagnosis of vascular conditions, Curefab enables healthcare professionals to monitor cancer therapies effectively. Additionally, the company offers computed sonography systems that allow for the comparison and analysis of ultrasound image data, equipping physicians with relevant diagnostic parameters to make informed decisions.
Scopis
Seed Round in 2010
Scopis GmbH, founded in 2010 as a joint spin-off of Charité University Clinic Berlin and Fraunhofer IPK, specializes in developing and manufacturing navigation systems for minimally invasive surgeries, particularly in the fields of ENT, spine, cranio-maxillofacial, and neurosurgery. The company offers a range of products, including the Scopis TGS for navigated functional endoscopic sinus surgery and the Hybrid Navigation System, which integrates with endoscopic towers to provide high-definition documentation. Scopis also produces various EM instruments, such as precision pointers, malleable suction tubes, and tracking devices. Additionally, the company provides planning software that facilitates the surgical process by allowing users to create and execute plans in the operating theater. Scopis operates a worldwide distribution network and is based in Berlin, Germany, as a subsidiary of Stryker Corporation.
Implandata Ophthalmic Products
Seed Round in 2010
Implandata Ophthalmic Products GmbH is a medical device company based in Hanover, Germany, founded in 2010. It specializes in developing innovative solutions for the treatment and management of glaucoma, a prevalent eye disease. The company's flagship product, Eyemate, is an implantable micro sensor designed for continuous intraocular pressure measurement. This biocompatible device allows for 24-hour monitoring without compromising the patient's vision or overall well-being. By integrating advanced medical technology with information technology, Implandata aims to enhance the efficiency of glaucoma therapy, benefiting patients, their families, and caregivers. The company's focus on addressing unmet needs in glaucoma care positions it as a significant player in the ophthalmic medical device sector.
SAW Instruments
Seed Round in 2010
SAW Instruments specializes in the development, manufacture, and distribution of analytical systems designed for the life sciences sector. The company's innovative equipment enables label-free analysis of biomolecular interactions, offering a combination of high sensitivity, stability, and user-friendliness. SAW Instruments' products are utilized by leading research institutions in Germany and Switzerland, reflecting their effectiveness and reliability in advanced scientific research.
PEPperPRINT
Seed Round in 2010
PEPperPRINT GmbH, based in Heidelberg, Germany, specializes in high-density peptide arrays and offers a versatile peptide microarray platform known as PEPperCHIP. This platform facilitates comprehensive proteome interaction analysis, antibody profiling, epitope mapping, and enzyme substrate profiling, among other applications. PEPperPRINT's customizable microarrays serve various research needs, including the design of peptide binders and the identification of biomarkers. The company also provides PEPperSCREEN services for the optimization of peptides and peptidomimetics for diagnostics, therapeutics, and drug development. Furthermore, PEPperPRINT offers PEPperSlide, which aids in the immobilization of biomolecules for microarray experiments and immunoassays. Founded in 2001, PEPperPRINT continues to deliver innovative solutions to enhance peptide research without requiring extensive laboratory infrastructure, thus providing a cost-effective approach for its clients.
SurgicEye
Series A in 2010
SurgicEye GmbH, founded in 2008 and headquartered in Munich, Germany, specializes in intra-operative imaging and instrument navigation solutions tailored for surgical procedures. The company offers several innovative products, including the declipse SPECT open surgery, a navigated radio-guided surgery system utilizing handheld 3-D freehand SPECT imaging technology; the declipse SPECT Laparascopy, an intraoperative 3D imaging system for performing invasive sentinel lymph node biopsies; and the declipse SPECT imaging probe, a mobile high-resolution SPECT imaging solution. Additionally, SurgicEye provides consulting services in medical device development, including requirement engineering, software specification, software development, and testing for medical devices, as well as support for designing and conducting clinical studies.
Eyetronic Therapie
Series B in 2010
EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.
Meidrix Biomedicals
Venture Round in 2010
Meidrix Biomedicals is a medical biotechnology company that specializes in medical devices for cartilage repair. Meidrix Biomedicals also offers regenerative and biological medical products. Meidrix Biomedicals was founded in 2009 and was headquartered in Bayern, Germany.
Transcatheter Technologies
Seed Round in 2009
TRANSCATHETER TECHNOLOGIES is developing a unique aortic valve implantation system that will increase the safety and durability of aortic valve implantation. The TRINITY repositionable transcatheter aortic valve system is at the forefront of next-generation transcatheter valve implantation technology. In the near future, transcatheter valve implantation will become the preferred therapy for aortic valve implantation, and TRANSCATHETER TECHNOLOGIES‘ goal is to provide the most advanced technology available.
PluriSelect
Venture Round in 2009
PluriSelect develops biotechnical devices and supplies focused on efficient tools for cell and protein separation. The company's products facilitate the isolation of cells from whole blood, buffy coat, cell culture, and other complex biological liquids, as well as the extraction of specific targets from unbound materials. By providing these solutions, PluriSelect supports researchers in academic science, helping them achieve high-quality results while saving time and resources in their routine tasks.
AVIDAL Vascular
Seed Round in 2009
AVIDAL Vascular GmbH, based in Berlin, Germany, develops medical devices for the treatment of coronary, peripheral, and neuro-vascular diseases. The company specializes in various products including drug eluting balloons, specialty catheters, embolic protection stents, and biodegradable stents. In addition to its focus on patient care, AVIDAL Vascular provides a platform for medical device manufacturers to enter the central European markets, offering a range of services such as regulatory affairs, clinical study support, marketing assistance, and logistics. Founded in 2009 by Torsten Heilmann, the company emphasizes comprehensive support in business development, customer service, and financial management, enhancing its capabilities in the healthcare sector.
Eyetronic Therapie
Seed Round in 2009
EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.
Microstim
Seed Round in 2009
Microstim GmbH specializes in developing implantable myostimulators aimed at providing tissue maintenance and functional support for the heart. The company focuses on advanced microcontroller technology for the acquisition and processing of data, as well as the control of cardiac and muscle stimulation impulses. Its innovative devices facilitate wireless communication within the body, enhancing patient monitoring and care. The myostimulators are designed to assist muscle-powered cardiac functions, allowing patients to monitor stimulation levels and preventing overstimulation that could jeopardize therapy. Microstim GmbH gained recognition for its business model by winning a national business plan contest in 2008, highlighting its potential in the medical technology sector.
SurgicEye
Seed Round in 2008
SurgicEye GmbH, founded in 2008 and headquartered in Munich, Germany, specializes in intra-operative imaging and instrument navigation solutions tailored for surgical procedures. The company offers several innovative products, including the declipse SPECT open surgery, a navigated radio-guided surgery system utilizing handheld 3-D freehand SPECT imaging technology; the declipse SPECT Laparascopy, an intraoperative 3D imaging system for performing invasive sentinel lymph node biopsies; and the declipse SPECT imaging probe, a mobile high-resolution SPECT imaging solution. Additionally, SurgicEye provides consulting services in medical device development, including requirement engineering, software specification, software development, and testing for medical devices, as well as support for designing and conducting clinical studies.
ILIAS-medical GmbH
Seed Round in 2008
Die ILIAS-medical GmbH entwickelt die kleinste mobile, künstliche Lunge der Welt
Sense Inside
Venture Round in 2008
Sense Inside develops a unique diagnostic and therapeutic device specifically for bruxism, the condition characterized by involuntary teeth grinding. This innovative device aims to offer long-term solutions for both diagnosis and treatment, addressing the significant physiological strain experienced by an increasing number of patients. By equipping healthcare professionals with a comprehensive tool, Sense Inside enhances the ability to diagnose and manage dental diseases associated with bruxism.
Heppe Medical Chitosan
Seed Round in 2008
Heppe Medical Chitosan GmbH, based in Halle, Germany, specializes in the development, production, and sale of biopolymers derived from chitin and chitosan for the cosmetic and pharmaceutical industries. Founded in 2005, the company produces pure chitin and chitosan, along with their derivatives and nanoparticulate forms, adhering to Good Manufacturing Practice (GMP) standards. These biodegradable and non-toxic biopolymers possess unique properties, such as bacteriostatic effects and the ability to bond with proteins and heavy metals. Heppe Medical Chitosan's products are utilized in applications including wound dressing, drug delivery, and tissue engineering, allowing for innovative solutions in healthcare and beauty.
Immunservice
Seed Round in 2008
Immunservice GmbH is engaged in the development and commercialization of biomimetic treatments aimed at cancer and infectious diseases. The company specializes in creating therapies based on immune hormones, particularly focusing on interleukin-2. Its flagship product, Pulmoleukin, is designed to prevent suffocation in patients with lung tumors by leveraging natural biomimetic approaches. Immunservice also addresses various orphan disease indications and offers services related to patent applications, biomimetic therapies, and clinical development. Founded in 2004 and based in Hamburg, Germany, the company emphasizes research on immune hormone interleukin-2 and provides insights for the advancement of diagnostic and pharmaceutical applications.
MEDOVENT
Seed Round in 2006
MEDOVENT GmbH was founded in summer 2006 by Dr. Thomas Freier and Dr. Rivelino Montenegro. Both have a long-term expertise in the field of biomaterial research and medical device development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.